SAVA

SAVA is a London-based startup that has developed a groundbreaking microsensing wearable device capable of detecting biomarkers just beneath the skin's surface in real-time. The company's first product is a smart, connected patch focused on glucose monitoring for people with diabetes, a condition projected to impact approximately 783 million adults by 2045. SAVA's microsensor offers painless, continuous, and affordable glucose monitoring, addressing the growing demand for continuous glucose monitoring (CGM) devices, a market worth USD 8.2 billion as of 2024 and growing at 10% annually.

SAVA's modular design allows for simultaneous monitoring of multiple molecules, enabling the platform to unlock a vast range of applications beyond diabetes, such as monitoring chronic conditions, wellbeing, drug adherence, and personalized therapy. The company gained approval from the UK's Medicines and healthcare Products Regulatory Agency (MHRA) in 2024 to conduct clinical trials on patients with diabetes.

SAVA's team has grown to over 40 people, including creators of CGMs from Abbott, Dexcom, and Medtronic. As of June 2024, the startup had raised USD 13 million from leading venture capital firms, angel investors, the European Union, and the UK Government's Innovate UK program. The funding will support team expansion, product development, and demonstrating clinical performance.